HDLighthouse.org

New to the Huntington's Disease Lighthouse?

Welcome to the HDlighthouse!

Getting started.

Home \ Treatment & Care \ Treatment \ Drugs \ Related \ Updates

HD Lighthouse Editors Comment: It may be a good idea to not treat chorea unless it is a problem for the patient. See: Chorea Awareness -- Jerry

Posted to HDLighthouse: 11-Sep-02

HDL Update: Huntington's Disease: A Randomized, Controlled Trial Using The NMDA-antagonist Amantadin

Reduces Chorea
"Results suggest that NMDA receptor supersensitivity may contribute to the clinical expression of choreiform dyskinesias in HD and that selective antagonists at that site can safely confer palliative benefit."

Amantadine Study

OBJECTIVE:

To examine the acute effects of the NMDA receptor antagonist amantadine on motor and cognitive function in Huntington's disease (HD).

BACKGROUND:

Chorea in HD and in the levodopa-induced dyskinesias of PD may be clinically indistinguishable. In PD, hyperphosphorylation of NMDA receptors expressed on striatal medium spiny neurons contributes to peak-dose dyskinesias, and drugs that block these receptors can diminish chorea severity. Because these spiny neurons are the primary target of the neurodegenerative process in HD, sensitization of NMDA receptors on residual striatal neurons might also participate in the generation of motor dysfunction in HD.

METHODS:

To evaluate this possibility, 24 patients with HD entered a double-blind placebo-controlled crossover study of amantadine with two 2-week arms.

RESULTS:

Chorea scores were lower with amantadine (usually 400 mg/d) than placebo, with a median reduction in extremity chorea at rest of 36% (p = 0.04) for all 22 evaluable patients and of 56% in the 10 individuals with the highest plasma drug levels. Improvement correlated with plasma amantadine concentrations (p = 0.01) but not CAG repeat length. Parkinsonian rating scores did not worsen and there was no consistent change in cognitive measures. Adverse event profile was benign.

CONCLUSIONS:

Results suggest that NMDA receptor supersensitivity may contribute to the clinical expression of choreiform dyskinesias in HD and that selective antagonists at that site can safely confer palliative benefit.

Source: Huntington's disease: A Randomized, Controlled Trial Using The NMDA-antagonist Amantadin, Neurology 2002 Sep 10;59(5):694-9, Verhagen Metman L.,et al.; Department of Neurological Sciences (Dr. Verhagen Metman and J. Wuu), Rush University/Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL.




	Read the HDAC/HDLighthouse Forum. Post your comments

...Huntington's families need to be actively included....

Marsha L. Miller, Ph.D.
Posted to HDL: 24 Aug 2004

**C0P1 CLINICAL TRIALS FOR HUNTINGTON'S
Proneuron Biotechnologies Inc. Announces Phase II Trial of Copolymer-1 for the Treatment of Patients with Huntington's Disease. Clinical Trial to ...
Jerry Lampson
Posted to HDL: 22 Sep 2003

Antipsychotics To Be Investigated
Dr. Sahebarao P. Mahadik and Dr. Alvin V. Terry Jr. are looking at the cognitive impact of long-term use of ...
Jerry Lampson
Posted to HDL: 18 Sep 2003

Lithium Cuts Suicide Rate in Bipolar Patients
The most widely prescribed treatment for manic depression in the United States carries a suicide risk that's as much as ...
Jerry Lampson
Posted to HDL: 17 Sep 2003

Lithium For Huntington's Disease Treatment
Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. ...
Jerry Lampson
Posted to HDL: 12 Aug 2003

Nurturing Medical Discoveries
Venture capitalists and drug companies are becoming reluctant to invest in academic medical discoveries, three leading California universities are planning ...
Jerry Lampson
Posted to HDL: 31 Jul 2003

Amantadine in Huntington Disease
Amantadine hydrochloride treatment at doses of 300 mg/d had no effect, on average, for Huntington chorea, although most patients felt ...
Jerry Lampson
Posted to HDL: 29 Jul 2003

Huntington's disease ACEi Treatment
We report on a woman with Huntington's disease whose condition deteriorated dramatically during treatment with the angiotensin converting enzyme inhibitor ...
Jerry Lampson
Posted to HDL: 10 Jul 2003

Treating Huntington's Disease Stress
Cell proliferation in adult hippocampus is decreased by inescapable stress and reversed by fluoxetine treatment ...
Jerry Lampson
Posted to HDL: 03 Jul 2003

****Statins Induce Neurogenesis
These data indicate that atorvastatin induced brain plasticity and has neurorestorative activity after experimental stroke. Statins induce angiogenesis, neurogenesis, and ...
Jerry Lampson
Posted to HDL: 05 Jun 2003 [an error occurred while processing this directive]


	Disclaimer & Privacy Policy \| Welcome \| Site Feedback Marsha@HDLighthouse.org